ATE339416T1 - Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen - Google Patents

Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen

Info

Publication number
ATE339416T1
ATE339416T1 AT02762067T AT02762067T ATE339416T1 AT E339416 T1 ATE339416 T1 AT E339416T1 AT 02762067 T AT02762067 T AT 02762067T AT 02762067 T AT02762067 T AT 02762067T AT E339416 T1 ATE339416 T1 AT E339416T1
Authority
AT
Austria
Prior art keywords
kinases
jnk
jun
inhibitors
terminal
Prior art date
Application number
AT02762067T
Other languages
English (en)
Inventor
Jingrong Cao
Jeremy Green
Young-Choon Moon
Jian Wang
Mark Ledeboer
Edmund Harrington
Huai Gao
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE339416T1 publication Critical patent/ATE339416T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AT02762067T 2001-04-13 2002-04-10 Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen ATE339416T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28362101P 2001-04-13 2001-04-13
US29297401P 2001-05-23 2001-05-23
US32944001P 2001-10-15 2001-10-15

Publications (1)

Publication Number Publication Date
ATE339416T1 true ATE339416T1 (de) 2006-10-15

Family

ID=27403408

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02762067T ATE339416T1 (de) 2001-04-13 2002-04-10 Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen

Country Status (12)

Country Link
US (2) US6642227B2 (de)
EP (1) EP1389206B1 (de)
JP (1) JP2004535381A (de)
AR (1) AR035824A1 (de)
AT (1) ATE339416T1 (de)
AU (1) AU2002338642A1 (de)
CA (1) CA2443487A1 (de)
DE (1) DE60214701T2 (de)
ES (1) ES2271322T3 (de)
MX (1) MXPA03009378A (de)
TW (1) TWI235752B (de)
WO (1) WO2002083667A2 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912240A (en) * 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
CA2417960C (en) 2000-08-04 2012-07-10 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317452B1 (de) * 2000-09-15 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazolverbindungen als protein-kinasehemmer
US6653301B2 (en) 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
ATE339418T1 (de) * 2001-06-01 2006-10-15 Vertex Pharma Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
MXPA04007697A (es) * 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh) * 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
CN104095851A (zh) 2003-05-15 2014-10-15 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
EP1694671A2 (de) * 2003-12-04 2006-08-30 Vertex Pharmaceuticals Incorporated Als inhibitoren von proteinkinasen geeignete chinoxaline
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
JP2007531757A (ja) * 2004-03-30 2007-11-08 カイロン コーポレイション 抗癌剤としての置換チオフェン誘導体
JP2007538063A (ja) * 2004-05-20 2007-12-27 スージェン， インク． チオフェンヘテロアリールアミン
US20050267556A1 (en) * 2004-05-28 2005-12-01 Allan Shuros Drug eluting implants to prevent cardiac apoptosis
WO2005123719A1 (en) * 2004-06-10 2005-12-29 Irm Llc Compounds and compositions as protein kinase inhibitors
US20060018123A1 (en) * 2004-07-02 2006-01-26 Rose Eric P Curing light having a reflector
WO2006044457A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
EP2258704A1 (de) 2004-10-19 2010-12-08 ArQule, Inc. Synthese aus Imidazooxazol- und Imidazothiazol-hemmern der P38-map-kinase
WO2006055831A2 (en) * 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
AU2006205220B2 (en) * 2005-01-10 2012-09-13 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
US20080194561A1 (en) * 2005-07-26 2008-08-14 Jerry Leroy Adams Compounds
US7737151B2 (en) * 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
CA2622352C (en) * 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
ES2533241T3 (es) * 2005-11-03 2015-04-08 Vertex Pharmaceuticals Incorporated Aminopirimidinas útiles como inhibidores de cinasas
WO2007053776A1 (en) * 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
WO2008034161A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
EP2086965B1 (de) * 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
WO2008077086A1 (en) * 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
JP5520057B2 (ja) * 2007-03-09 2014-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
WO2008112651A2 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP2152696B1 (de) * 2007-05-02 2014-09-24 Vertex Pharmaceuticals Incorporated Aminopyrimidine als kinasehemmer
MX2009011810A (es) 2007-05-02 2010-01-14 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
CN101679387A (zh) * 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
WO2008147626A2 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
AU2008282156B2 (en) * 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
EP2250160B1 (de) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophen-derivate und ihre verwendung als phosphatidylinositol 3-kinase (pi3k) inhibitoren
AU2009214440B2 (en) 2008-02-15 2014-09-25 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US8133861B2 (en) * 2008-02-29 2012-03-13 Alseres Pharmaceuticals, Inc. Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
US8217047B2 (en) 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
ES2605815T3 (es) * 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1
CN102215816A (zh) * 2008-09-03 2011-10-12 沃泰克斯药物股份有限公司 共晶和包含所述共晶的药物制剂
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2750935A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8450363B2 (en) * 2009-02-06 2013-05-28 Elan Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
WO2011034962A2 (en) 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
KR101682092B1 (ko) * 2009-11-12 2016-12-05 삼성디스플레이 주식회사 박막 트랜지스터 표시판 및 이를 포함하는 액정 표시 장치
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2013536193A (ja) 2010-08-11 2013-09-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリール類およびその使用
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2613786A4 (de) 2010-09-07 2013-10-23 Dmi Acquisition Corp Behandlung von erkrankungen
WO2012051410A2 (en) 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CA2815330A1 (en) * 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
CN103841987B (zh) 2011-10-10 2015-06-17 安皮奥制药股份有限公司 退行性关节病的治疗
BR112014007657A2 (pt) 2011-10-10 2017-04-11 Ampio Pharmaceuticals Inc dispositivos médicos implantáveis com tolerância imune aperfeiçoada e métodos para produção e implantação
BR112014008036A2 (pt) 2011-10-28 2017-04-11 Ampio Pharmaceuticals Inc tratamento de rinite
US10189825B2 (en) 2012-02-08 2019-01-29 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN106986863B (zh) 2012-04-24 2019-12-31 沃泰克斯药物股份有限公司 Dna-pk抑制剂
CN105246883B (zh) 2013-03-12 2017-07-21 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
PL3424920T3 (pl) 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
CN106604915A (zh) 2014-08-18 2017-04-26 安皮奥制药股份有限公司 关节病症的治疗
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
JP7187437B2 (ja) 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク 化合物および組成物ならびにそれらの使用
JP6654116B2 (ja) * 2016-08-12 2020-02-26 浜松ホトニクス株式会社 リニアイメージセンサおよびその製造方法
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
US20220411398A1 (en) * 2019-06-24 2022-12-29 University Of Iowa Research Foundation Jnk inhibitors as anticancer agents
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
TW202332448A (zh) * 2021-11-15 2023-08-16 美商艾瑞斯卡公司 噻吩ulk1/2抑制劑及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940712A (en) 1989-05-26 1990-07-10 Pfizer Inc. Derivatives of hydroxyprimidines as leukotriene synthesis inhibitors
IL112290A (en) 1994-01-12 1999-01-26 Novartis Ag Transformed aryl and the troiryl pyrimidines and herbicides containing them
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
CA2230896A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
AU6645998A (en) 1996-12-23 1998-07-17 Du Pont Pharmaceuticals Company Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
BR9809451A (pt) * 1997-05-22 2000-06-20 Searle & Co Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
AU732406B2 (en) * 1997-10-03 2001-04-26 Merck Frosst Canada & Co. Aryl thiophene derivatives as PDE IV inhibitors
CN1222520C (zh) * 1999-08-12 2005-10-12 沃泰克斯药物股份有限公司 c－JUN N－末端激酶(JNK)和其它蛋白激酶的抑制剂
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds

Also Published As

Publication number Publication date
MXPA03009378A (es) 2004-01-29
WO2002083667A2 (en) 2002-10-24
DE60214701T2 (de) 2007-09-13
ES2271322T3 (es) 2007-04-16
TWI235752B (en) 2005-07-11
US7084159B2 (en) 2006-08-01
CA2443487A1 (en) 2002-10-24
JP2004535381A (ja) 2004-11-25
EP1389206B1 (de) 2006-09-13
AU2002338642A1 (en) 2002-10-28
DE60214701D1 (de) 2006-10-26
US20040023963A1 (en) 2004-02-05
AR035824A1 (es) 2004-07-14
US6642227B2 (en) 2003-11-04
EP1389206A2 (de) 2004-02-18
US20030096816A1 (en) 2003-05-22
WO2002083667A3 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
ATE339416T1 (de) Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
DE60039616D1 (de) INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
DE60223790D1 (de) Hemmer von c-jun-terminal kinase (jnk) und andere protein kinase
NO20045677D0 (no) Inhibitorer av JAK- og CDK2-proteinkinaser
ATE414699T1 (de) Inhibitoren von tyrosinkinasen
ATE370123T1 (de) 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen
ATE324586T1 (de) Nitrit-stabilisierte zusammensetzungen von tetrazolium-reagenz und methoden derer nutzung
NO20015045D0 (no) Diaminotiazoler og deres anvendelse til inhibering av proteinkinaser
IL161576A0 (en) Benzimidazoles and analogues and their use as protein kinases inhibitors
ATE299881T1 (de) 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
ATE410421T1 (de) P38 inhibitor und anwendungsverfahren dafür
NO20025489L (no) Stabiliserte tetrasolium-fenasin-reagens-sammensetninger og fremgangsmåterfor deres anvendelse
IL158516A0 (en) Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
ATE508129T1 (de) Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole
EE05432B1 (et) Prroloprimidiinid kui valgukinaasi inhibiitorid
EP1517724A4 (de) Antiangiogene proteine und fragmente sowie verfahren zur verwendung davon
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
MXPA03009257A (es) Derivados de isoxaxol como inhibidores de src y otras proteinas cinasas.
DE60309255D1 (de) Abbildung und Entnahme von Gel
ATE321547T1 (de) Halogenierte aminobenzophenonen und aminobenzoylpyridinen als inhibitoren von il-1 und tnf
DK1389100T3 (da) Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties